Novavax, Inc.
NVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $1 | $11 |
| - Cash | $1 | $1 | $1 | $2 |
| + Debt | $0 | $0 | $1 | $0 |
| Enterprise Value | $1 | $0 | $0 | $10 |
| Revenue | $1 | $1 | $2 | $0 |
| % Growth | 22.6% | -65.2% | 709.3% | – |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 70.3% | 38.2% | 43.5% | 100% |
| EBITDA | -$0 | -$0 | -$1 | -$2 |
| % Margin | -15.8% | -87.6% | -37.8% | -850.7% |
| Net Income | -$0 | -$1 | -$1 | -$2 |
| % Margin | -27.5% | -98% | -41.1% | -882.5% |
| EPS Diluted | -1.23 | -5.41 | -8.42 | -23.44 |
| % Growth | 77.3% | 35.7% | 64.1% | – |
| Operating Cash Flow | -$0 | -$1 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$1 | -$1 | $0 |